Advertisement

Topics

CORRECTED-UPDATE 1-Novartis's Zykadia gets positive results, faces Roche pressure

03:29 EDT 23 Sep 2016 | Reuters

ZURICH, Sept 23 (Reuters) - Novartis's Zykadia drug performed well against a rare form of lung cancer, the Swiss company said on Friday, citing a study it hopes will help it win expanded regulatory approval for the use of the drug.

Original Article: CORRECTED-UPDATE 1-Novartis's Zykadia gets positive results, faces Roche pressure

NEXT ARTICLE

More From BioPortfolio on "CORRECTED-UPDATE 1-Novartis's Zykadia gets positive results, faces Roche pressure"

Quick Search
Advertisement
 

Relevant Topics

Novartis
Novartis is the fourth largest pharmaceutical company in the world, based on annual sales, which are exceeded $36,000m in 2009. Founded in 1996, Novartis focuses of four main areas; pharmaceuticals, vaccines & diagnostics, generic medicines and biosi...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...